Please ensure Javascript is enabled for purposes of website accessibility

Why Fluidigm Stock Plunged Today

By Joe Tenebruso – Aug 27, 2020 at 6:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The coronavirus testing market is suddenly a lot more crowded.

What happened

Shares of Fluidigm (FLDM -2.65%) plummeted on Thursday after a powerful rival announced a major development in the COVID-19 diagnostic race.

So what 

What a difference a day makes. After soaring 30% on Wednesday following news that its saliva-based coronavirus test had received an emergency use authorization from the U.S. Food and Drug Administration (FDA), Fluidigm gave up all of those gains today.

A stock chart that rises then falls, with a section that continued to rise wiped away.

Fluidigm's stock made a round trip over the past two days. Image source: Getty Images.

Yesterday, investors were excited about the potentially massive market opportunity for Fluidigm's new test. Today, however, they're decidedly less so, following news that healthcare giant Abbott Laboratories (ABT -1.56%) had also been granted an emergency use authorization by the FDA. 

Now what 

Abbott's test reportedly costs only $5 and can deliver results in just 15 minutes. It also requires no special lab equipment. And its results can be displayed via a free app that Abbott says could potentially be used as a "temporary digital health pass." The healthcare titan expects demand to be strong for its new test, and it's ramping up production to be able to provide 50 million tests per month beginning in October. 

For these reasons -- and although it's not a saliva-based test, like that of Fluidigm -- Abbott's test is considered to be a major breakthrough in the battle against COVID-19. In turn, investors reset their growth expectations for Fluidigm, and its stock price fell in kind.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Fluidigm Corporation Stock Quote
Fluidigm Corporation
$1.10 (-2.65%) $0.03
Abbott Laboratories Stock Quote
Abbott Laboratories
$96.76 (-1.56%) $-1.53

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.